Concomitant use of a fibrate and a statin may offer a therapeutic advantage to patients with dyslipidemia, especially in patients whose low-density lipoprotein cholesterol is controlled by statins but whose high-density lipoprotein cholesterol or triglycerides, or both, are not within goal. However, concern about drug-drug interactions may preclude optimal use of combination statin-fibrate therapy. This article reviews the pharmacokinetics between statins and fibrates, addressing risks associated with drug-drug interactions and combination therapy. (copyright) 2005 Elsevier Inc. All rights reserved.

Pharmacokinetic interactions between statins and fibrates / A. Corsini, S. Bellosta, M.H. Davidson. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - 96:9 SUPPL. 1(2005), pp. 44K-49K.

Pharmacokinetic interactions between statins and fibrates

A. Corsini
Primo
;
S. Bellosta
Secondo
;
2005

Abstract

Concomitant use of a fibrate and a statin may offer a therapeutic advantage to patients with dyslipidemia, especially in patients whose low-density lipoprotein cholesterol is controlled by statins but whose high-density lipoprotein cholesterol or triglycerides, or both, are not within goal. However, concern about drug-drug interactions may preclude optimal use of combination statin-fibrate therapy. This article reviews the pharmacokinetics between statins and fibrates, addressing risks associated with drug-drug interactions and combination therapy. (copyright) 2005 Elsevier Inc. All rights reserved.
cholesterol blood level; conference paper; coronary artery disease; diabetes mellitus; drug absorption; drug half life; drug safety; dyslipidemia; human; myopathy; priority journal; protein binding; protein metabolism; rhabdomyolysis; risk factor; triacylglycerol blood level; amprenavir; antibiotic agent; atorvastatin; azithromycin; clarithromycin; cyclosporin; digoxin; diltiazem; erythromycin; fenofibrate; fibric acid derivative; fluindostatin; gemfibrozil; glimepiride; hydroxymethylglutaryl coenzyme A reductase inhibitor; itraconazole; ketoconazole; mevinolin; mibefradil; nefazodone; nicotinic acid; pioglitazone; pravastatin; pyrrole derivative; repaglinide; rosiglitazone; rosuvastatin; simvastatin; unindexed drug; warfarin
Settore BIO/14 - Farmacologia
2005
Article (author)
File in questo prodotto:
File Dimensione Formato  
2005 Am J Cardiol Pharmacokinetic interactions.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 163.78 kB
Formato Adobe PDF
163.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/4699
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 57
social impact